Breaking News, Financial News

Moderna’s 4Q Results Impacted by Drop in COVID Vax Sales

Product sales for the quarter were down 30%, primarily driven by lower sales volume and the related manufacturing ramp up in 4Q21.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Moderna 4Q Revenues: $5.1 billion (-29%) 4Q Earnings: $1.5 billion (-70%) FY Revenues: $19.3 billion (-4%) FY Earnings: $8.4 billion (-31%) Comments: Results in the quarter impacted by a decrease in COVID-19 vaccines sales. Product sales for the quarter were $4.9 billion, down 30%, primarily driven by lower sales volume and the related manufacturing ramp up in 4Q21.   Spikevax Bivalent BA.4/BA.5 authorized under EUA in the U.S. as a booster dose for all age groups from 5 months. Moderna w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters